
Zymeworks Investor Relations Material
Latest events

Q1 2025
Zymeworks
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Zymeworks Inc
Access all reports
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific, multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's proprietary Azymetric platform combines its modular and flexible Fc engineering with non-Fc-containing domains designed to enable modulation of therapeutic index in order to address multiple biological targets simultaneously from a single protein. The partnering team brings together a comprehensive set of skills and expertise spanning early drug discovery through product commercialization.
Key slides for Zymeworks Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Zymeworks Inc


Q3 2024
Zymeworks Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ZYME
Country
🇺🇸 United States